14 results on '"Lorenzo, María M."'
Search Results
2. Genes A27L and F13L as Genetic Markers for the Isolation of Recombinant Vaccinia Virus
- Author
-
Lorenzo, María M., Sánchez-Puig, Juana M., and Blasco, Rafael
- Published
- 2019
- Full Text
- View/download PDF
3. Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models.
- Author
-
Lorenzo, María M., Marín-López, Alejandro, Chiem, Kevin, Jimenez-Cabello, Luis, Ullah, Irfan, Utrilla-Trigo, Sergio, Calvo-Pinilla, Eva, Lorenzo, Gema, Moreno, Sandra, Ye, Chengjin, Park, Jun-Gyu, Matía, Alejandro, Brun, Alejandro, Sánchez-Puig, Juana M., Nogales, Aitor, Mothes, Walther, Uchil, Pradeep D., Kumar, Priti, Ortego, Javier, and Fikrig, Erol
- Subjects
VACCINIA ,SARS-CoV-2 ,CELL fusion ,LABORATORY mice ,GOLDEN hamster - Abstract
The COVID-19 pandemic has underscored the importance of swift responses and the necessity of dependable technologies for vaccine development. Our team previously developed a fast cloning system for the modified vaccinia virus Ankara (MVA) vaccine platform. In this study, we reported on the construction and preclinical testing of a recombinant MVA vaccine obtained using this system. We obtained recombinant MVA expressing the unmodified full-length SARS-CoV-2 spike (S) protein containing the D614G amino-acid substitution (MVA-Sdg) and a version expressing a modified S protein containing amino-acid substitutions designed to stabilize the protein a in a pre-fusion conformation (MVA-Spf). S protein expressed by MVA-Sdg was found to be expressed and was correctly processed and transported to the cell surface, where it efficiently produced cell–cell fusion. Version Spf, however, was not proteolytically processed, and despite being transported to the plasma membrane, it failed to induce cell–cell fusion. We assessed both vaccine candidates in prime-boost regimens in the susceptible transgenic K18-human angiotensin-converting enzyme 2 (K18-hACE2) in mice and in golden Syrian hamsters. Robust immunity and protection from disease was induced with either vaccine in both animal models. Remarkably, the MVA-Spf vaccine candidate produced higher levels of antibodies, a stronger T cell response, and a higher degree of protection from challenge. In addition, the level of SARS-CoV-2 in the brain of MVA-Spf inoculated mice was decreased to undetectable levels. Those results add to our current experience and range of vaccine vectors and technologies for developing a safe and effective COVID-19 vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping
- Author
-
Duraffour, Sophie, Lorenzo, María M., Zöller, Gudrun, Topalis, Dimitri, Grosenbach, Doug, Hruby, Dennis E., Andrei, Graciela, Blasco, Rafael, Meyer, Hermann, and Snoeck, Robert
- Published
- 2015
- Full Text
- View/download PDF
5. Vaccinia virus and Cowpox virus are not susceptible to the interferon-induced antiviral protein MxA.
- Author
-
Lorenzo, María M., Sanchez-Puig, Juana M., and Blasco, Rafael
- Subjects
- *
VACCINIA , *INTERFERONS , *RNA viruses , *ANTIVIRAL agents , *MONKEYPOX virus , *AFRICAN swine fever virus , *DNA viruses - Abstract
MxA protein is expressed in response to type I and type III Interferon and constitute an important antiviral factor with broad antiviral activity to diverse RNA viruses. In addition, some studies expand the range of MxA antiviral activity to include particular DNA viruses like Monkeypox virus (MPXV) and African Swine Fever virus (ASFV). However, a broad profile of activity of MxA to large DNA viruses has not been established to date. Here, we investigated if some well characterized DNA viruses belonging to the Poxviridae family are sensitive to human MxA. A cell line inducibly expressing MxA to inhibitory levels showed no anti-Vaccinia virus (VACV) virus activity, indicating either lack of susceptibility of the virus, or the existence of viral factors capable of counteracting MxA inhibition. To determine if VACV resistance to MxA was due to a virus-encoded anti-MxA activity, we performed coinfections of VACV and the MxA-sensitive Vesicular Stomatitis virus (VSV), and show that VACV does not protect VSV from MxA inhibition in trans. Those results were extended to several VACV strains and two CPXV strains, thus confirming that those Orthopoxviruses do not block MxA action. Overall, these results point to a lack of susceptibility of the Poxviridae to MxA antiviral activity. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. INTRODUCCIÓN.
- Author
-
GARCÍA LORENZO, María M.
- Subjects
LITERATURE & science ,CULTURAL identity ,CULTURAL fusion - Abstract
Copyright of Signa is the property of Editorial UNED and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2014
7. A Vaccinia Virus Recombinant Transcribing an Alphavirus Replicon and Expressing Alphavirus Structural Proteins Leads to Packaging of Alphavirus Infectious Single Cycle Particles.
- Author
-
Sánchez-Puig, Juana M., Lorenzo, María M., and Blasco, Rafael
- Subjects
- *
VACCINIA , *RECOMBINANT viruses , *ALPHAVIRUSES , *VIRAL replicons , *GENE expression in viruses , *CYTOSKELETAL proteins , *GENETIC vectors - Abstract
Poxviruses and Alphaviruses constitute two promising viral vectors that have been used extensively as expression systems, or as vehicles for vaccine purposes. Poxviruses, like vaccinia virus (VV) are well-established vaccine vectors having large insertion capacity, excellent stability, and ease of administration. In turn, replicons derived from Alphaviruses like Semliki Forest virus (SFV) are potent protein expression and immunization vectors but stocks are difficult to produce and maintain. In an attempt to demonstrate the use of a Poxvirus as a means for the delivery of small vaccine vectors, we have constructed and characterized VV/SFV hybrid vectors. A SFV replicon cDNA was inserted in the VV genome and placed under the control of a VV early promoter. The replicon, transcribed from the VV genome as an early transcript, was functional, and thus capable of initiating its own replication and transcription. Further, we constructed a VV recombinant additionally expressing the SFV structural proteins under the control of a vaccinia synthetic early/late promoter. Infection with this recombinant produced concurrent transcription of the replicon and expression of SFV structural proteins, and led to the generation of replicon-containing SFV particles that were released to the medium and were able to infect additional cells. This combined VV/SFV system in a single virus allows the use of VV as a SFV delivery vehicle in vivo. The combination of two vectors, and the possibility of generating in vivo single-cycle, replicon containing alphavirus particles, may open new strategies in vaccine development or in the design of oncolytic viruses. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
8. Vaccinia Virus A34 Glycoprotein Determines the Protein Composition of the Extracellular Virus Envelope.
- Author
-
Perdiguero, Beatriz, Lorenzo, María M., and Blasco, Rafael
- Subjects
- *
VACCINIA , *VIRAL proteins , *GLYCOPROTEINS , *PROTEINS , *VIRAL envelopes , *VIRUSES - Abstract
The outer envelope of the extracellular form of vaccinia virus contains five virus-encoded proteins, F13, A33, A34, A56, and B5, that, with the exception of A56, are implicated in virus egress or infectivity. A34, a type II transmembrane glycoprotein, is involved in the induction of actin tails, the release of enveloped virus from the surfaces of infected cells, and the disruption of the virus envelope after ligand binding prior to virus entry. To investigate interactions between A34 and other envelope proteins, a recombinant vaccinia virus (vA34RHA) expressing an epitope-tagged version of A34 (A34HA) was constructed by appending an epitope from influenza virus hemagglutinin to the C terminus of A34. Complexes of A34HA with B5 and A36, but not with A33 or F13, were detected in vA34RHA-infected cells. A series of vaccinia viruses expressing mutated versions of the B5 protein was used to investigate the domain(s) of B5 required for interaction with A34. Both the cytoplasmic and the transmembrane domains of B5 were dispensable for binding to A34. Most of the extracellular domain of B5, which contains four short consensus repeats homologous to complement control proteins, was sufficient for A34 interaction, indicating that both proteins interact through their ectodomains. Immunofluorescence experiments on cells infected with A34-deficient virus indicated that A34 is required for efficient targeting of B5, A36, and A33 into wrapped virions. Consistent with this observation, the envelope of A34-deficient virus contained normal amounts of F13 but decreased amounts of A33 and B5 with respect to the parental WR virus. These results point to A34 as a major determinant in the protein composition of the vaccinia virus envelope. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
9. DIVERSITY-BASED SELECTION OF LEARNING ALGORITHMS: A BAGGING APROACH.
- Author
-
Cabrera-Hernández, Leidys, Morales Hernández, Alejandro, Meneses Gómez, Maricel, Meneses Marcel, Alfredo, Casas Cardoso, Gladys M., and García Lorenzo, María M.
- Subjects
- *
BOOTSTRAP aggregation (Algorithms) , *MACHINE learning - Abstract
Nowadays, classification problems are becoming increasingly important in many real-world applications. As the problems become more complex and the consequences of a bad decision are more serious, more advanced techniques, as the combination of classifiers, need to be applied. When combining classifiers, it is important to ensure diversity between them as it does not make sense to combine classifiers whose classification is the same. There are several techniques to ensure diversity in systems like these and generally it consider modify the data set, use different learning algorithms or make a process of improvement or learning on the individual classification. Although the relationship between diversity and system accuracy has not been fully established, it is clear that diversity remains a factor to be taken into account in the construction of multiclassifiers. In this paper we present a modification to the bagging algorithm to consider different learning algorithms during the training process and optimize the classifiers built to obtain diverse systems and as accurate as possible. Executed simulations suggest the use of the Double Failure pairwise measure to quantify the diversity of the system. With respect to the number of classifiers used, it was observed that the systems built had approximately half of the total classifiers they should have. After, the superiority of the proposed method with respect to five state-of-the-art multiclassifiers was verified and it is suggested the incorporation of a learning process like the one executed in Stacking. Finally, are shown results in biochemical real applications and the general conclusions are exposed. [ABSTRACT FROM AUTHOR]
- Published
- 2021
10. Vaccinia Virus Attenuation by Codon Deoptimization of the A24R Gene for Vaccine Development.
- Author
-
Lorenzo MM, Nogales A, Chiem K, Blasco R, and Martínez-Sobrido L
- Subjects
- Animals, Codon, Vaccine Development, Vaccines, Attenuated genetics, Vaccinia virus genetics, Viral Replicase Complex Proteins, Poxviridae genetics, Smallpox, Viral Vaccines genetics, Viruses genetics
- Abstract
Poxviruses have large DNA genomes, and they are able to infect multiple vertebrate and invertebrate animals, including humans. Despite the eradication of smallpox, poxvirus infections still remain a significant public health concern. Vaccinia virus (VV) is the prototypic member in the poxviridae family and it has been used extensively for different prophylactic applications, including the generation of vaccines against multiple infectious diseases and/or for oncolytic treatment. Many attempts have been pursued to develop novel attenuated forms of VV with improved safety profiles for their implementation as vaccines and/or vaccines vectors. We and others have previously demonstrated how RNA viruses encoding codon-deoptimized viral genes are attenuated, immunogenic and able to protect, upon a single administration, against challenge with parental viruses. In this study, we employed the same experimental approach based on the use of misrepresented codons for the generation of a recombinant (r)VV encoding a codon-deoptimized A24R gene, which is a key component of the viral RNA polymerase. Similar to our previous studies with RNA viruses, the A24R codon-deoptimized rVV (v-A24cd) was highly attenuated in vivo but able to protect, after a single intranasal dose administration, against an otherwise lethal challenge with parental VV. These results indicate that poxviruses can be effectively attenuated by synonymous codon deoptimization and open the possibility of using this methodology alone or in combination with other experimental approaches for the development of attenuated vaccines for the treatment of poxvirus infection, or to generate improved VV-based vectors. Moreover, this approach could be applied to other DNA viruses. IMPORTANCE The family poxviridae includes multiple viruses of medical and veterinary relevance, being vaccinia virus (VV) the prototypic member in the family. VV was used during the smallpox vaccination campaign to eradicate variola virus (VARV), which is considered a credible bioterrorism threat. Because of novel innovations in genetic engineering and vaccine technology, VV has gained popularity as a viral vector for the development of vaccines against several infectious diseases. Several approaches have been used to generate attenuated VV for its implementation as vaccine and/or vaccine vector. Here, we generated a rVV containing a codon-deoptimized A24R gene (v-A24cd), which encodes a key component of the viral RNA polymerase. v-A24cd was stable in culture cells and highly attenuated in vivo but able to protect against a subsequent lethal challenge with parental VV. Our findings support the use of this approach for the development of safe, stable, and protective live-attenuated VV and/or vaccine vectors.
- Published
- 2022
- Full Text
- View/download PDF
11. Mutagenesis of the palmitoylation site in vaccinia virus envelope glycoprotein B5.
- Author
-
Lorenzo MM, Sánchez-Puig JM, and Blasco R
- Subjects
- Fluorescent Antibody Technique, Humans, Mutagenesis, Site-Directed methods, Palmitates metabolism, Vaccinia transmission, Vaccinia virus physiology, Viral Envelope Proteins metabolism, Viral Envelope Proteins physiology, Viral Matrix Proteins metabolism, Virus Assembly genetics, Lipoylation genetics, Vaccinia virology, Vaccinia virus genetics, Viral Envelope Proteins genetics, Viral Matrix Proteins genetics
- Abstract
The outer envelope of vaccinia virus extracellular virions is derived from intracellular membranes that, at late times in infection, are enriched in several virus-encoded proteins. Although palmitoylation is common in vaccinia virus envelope proteins, little is known about the role of palmitoylation in the biogenesis of the enveloped virus. We have studied the palmitoylation of B5, a 42 kDa type I transmembrane glycoprotein comprising a large ectodomain and a short (17 aa) cytoplasmic tail. Mutation of two cysteine residues located in the cytoplasmic tail in close proximity to the transmembrane domain abrogated palmitoylation of the protein. Virus mutants expressing non-palmitoylated versions of B5 and/or lacking most of the cytoplasmic tail were isolated and characterized. Cell-to-cell virus transmission and extracellular virus formation were only slightly affected by those mutations. Notably, B5 versions lacking palmitate showed decreased interactions with proteins A33 and F13, but were still incorporated into the virus envelope. Expression of mutated B5 by transfection into uninfected cells showed that both the cytoplasmic tail and palmitate have a role in the intracellular transport of B5. These results indicate that the C-terminal portion of protein B5, while involved in protein transport and in protein-protein interactions, is broadly dispensable for the formation and egress of infectious extracellular virus and for virus transmission.
- Published
- 2012
- Full Text
- View/download PDF
12. Isolation of recombinant MVA using F13L selection.
- Author
-
Sánchez-Puig JM, Lorenzo MM, and Blasco R
- Subjects
- Animals, Base Sequence, Cells, Cultured, Cloning, Molecular, Cricetinae, DNA, Recombinant, Gene Knockout Techniques, Genetic Markers, Promoter Regions, Genetic, Transduction, Genetic, Vaccinia virus growth & development, Viral Load, Virus Cultivation, Membrane Proteins genetics, Vaccinia virus genetics, Vaccinia virus isolation & purification, Viral Envelope Proteins genetics
- Abstract
Modified vaccinia virus Ankara (MVA) has become a widely used vector for vaccine and laboratory purposes. Despite significant advances in recombinant MVA technology, the isolation of recombinant viruses remains a tedious and difficult process. This chapter describes the use of an efficient and easy-to-use selection system adapted for MVA. The system is based on the requirement of the viral gene F13L for efficient virus spread in cell culture, which results in a severe block in virus transmission when F13L gene is deleted (Blasco R, Moss B. J Virol 65:5910-5920, 1991; Blasco R, Moss B. J Virol 66:4170-4179, 1992). The insertion of foreign genes in the MVA genome is accomplished by recombination of a transfected plasmid carrying the foreign genes and the F13L with the genome of an F13L knockout virus. Subsequently, selection of virus recombinants is carried out by serial passage and/or plaque purification of viruses that have recovered the F13L gene.
- Published
- 2012
- Full Text
- View/download PDF
13. Construction and isolation of recombinant vaccinia virus using genetic markers.
- Author
-
Lorenzo MM, Galindo I, and Blasco R
- Subjects
- Animals, Genetic Vectors, Hypoxanthine Phosphoribosyltransferase genetics, Vaccinia virus immunology, Vaccinia virus isolation & purification, DNA, Recombinant, Genetic Markers genetics, Vaccinia virus genetics
- Abstract
The standard approach for the isolation of vaccinia virus recombinants involves homologous recombination between a transfected plasmid and the replicating viral DNA. In a typical infection/transfection experiment, recombinant viruses only account for a tiny proportion (10-4 to 10-3) of the progeny virus; thus, genetic markers are often included in the transfected plasmid to facilitate the selection of recombinant viruses. This chapter describes in detail two different selection procedures: one relies on plaque formation phenotype using the vaccinia virus gene F13L; the other relies on antibiotic resistance using the Escherichia coli xanthine-guanine phosphoribosyl transferase gene.
- Published
- 2004
- Full Text
- View/download PDF
14. Movements of vaccinia virus intracellular enveloped virions with GFP tagged to the F13L envelope protein.
- Author
-
Geada MM, Galindo I, Lorenzo MM, Perdiguero B, and Blasco R
- Subjects
- Animals, Blotting, Western, Cell Line, Cricetinae, Green Fluorescent Proteins, Luminescent Proteins genetics, Membrane Proteins genetics, Microscopy, Fluorescence, Microscopy, Video, Microtubules physiology, Protein Transport, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins metabolism, Vaccinia virus genetics, Viral Envelope Proteins genetics, Virion genetics, Luminescent Proteins metabolism, Membrane Proteins metabolism, Vaccinia virology, Vaccinia virus physiology, Viral Envelope Proteins metabolism, Virion physiology
- Abstract
Vaccinia virus produces several forms of infectious virions. Intracellular mature virions (IMV) assemble in areas close to the cell nucleus. Some IMV acquire an envelope from intracellular membranes derived from the trans-Golgi network, producing enveloped forms found in the cytosol (intracellular enveloped virus; IEV), on the cell surface (cell-associated enveloped virus) or free in the medium (extracellular enveloped virus; EEV). Blockage of IMV envelopment inhibits transport of virions to the cell surface, indicating that enveloped virus forms are required for virion movement from the Golgi area. To date, the induction of actin tails that propel IEV is the only well-characterized mechanism for enveloped virus transport. However, enveloped virus transport and release occur under conditions where actin tails are not formed. In order to study these events, recombinant vaccinia viruses were constructed with GFP fused to the most abundant protein in the EEV envelope, P37 (F13L). The P37-GFP fusion, like normal P37, accumulated in the Golgi area and was incorporated efficiently into enveloped virions. These recombinants allowed the monitoring of enveloped virus movements in vivo. In addition to a variety of relatively slow movements (<0.4 microm/s), faster, saltatory movements both towards and away from the Golgi area were observed. These movements were different from those dependent on actin tails and were inhibited by the microtubule-disrupting drug nocodazole, but not by the myosin inhibitor 2,3-butanedione monoxime. Video microscopy (5 frames per s) revealed that saltatory movements had speeds of up to, and occasionally more than, 3 microm/s. These results suggest that a second, microtubule-dependent mechanism exists for intracellular transport of enveloped vaccinia virions.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.